Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study

NCT05831969 is registered in ClinicalTrials.gov with Shenyang Tenth People's Hospital as lead sponsor.

NCT NCT05831969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05831969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lenalidomide to Reverse Drug Resistance After Lenvatinib Combined With PD-1 Inhibitors in the First-line Treatment of Advanced HCC ：a Prospective, Exploratory, Single-arm, Open-label, Multi-center Clinical Study
Lead sponsor
Shenyang Tenth People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 5, 2023
Completion date
October 5, 2025
Enrollment
23 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hcc